about
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targetsProstate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysisThe role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2.Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study.Androgen deprivation therapy for prostate cancer: current status and future prospects.Hormones and prostate cancer: current perspectives and future directions.Prostate cancer and ambient pesticide exposure in agriculturally intensive areas in California.Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade diseaseTotal testosterone in young men is more closely associated than free testosterone with prostate cancer disparitiesRepeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention TrialHypogonadism in the man with erectile dysfunction: what to look for and when to treat.Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?Assay reproducibility of serum androgen measurements using liquid chromatography-tandem mass spectrometry.Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model.Association of uridine diphosphate-glucuronosyltransferase 2B gene variants with serum glucuronide levels and prostate cancer risk.Testosterone therapy for men at risk for or with history of prostate cancer.Do evolutionary life-history trade-offs influence prostate cancer risk? a review of population variation in testosterone levels and prostate cancer disparities.Novel biomarkers for risk of prostate cancer: results from a case-control study.Androgens and male aging: Current evidence of safety and efficacy.The role of testosterone in the pathogenesis of prostate cancer.UGT2B17 Polymorphism and Risk of Prostate Cancer: A Meta-Analysis.Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.Risk factors for prostate cancer.Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis.Adult-onset hypogonadism: evaluation and role of testosterone replacement therapy.Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels.Differing levels of testosterone and the prostate: a physiological interplay.The safety of testosterone supplementation therapy in prostate cancer.A biological approach to characterizing exposure to metalworking fluids and risk of prostate cancer (United States).Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy resultHighly elevated PSA and dietary PhIP intake in a prospective clinic-based study among African Americans.The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.Racial Differences in Age-Related Variations of Testosterone Levels Among US Males: Potential Implications for Prostate Cancer and Personalized Medication.Factors Associated With the Prevalence of Prostate Cancer in Rural Saskatchewan: The Saskatchewan Rural Health Study.Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml.Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation.Diabetes mellitus and cancer risk in a network of case-control studies.A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months.Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.
P2860
Q24629083-A7F09064-AA5C-46B6-9928-53FF1B76047AQ28166676-D51C155C-3906-4DD7-A31F-2CAE1ACEB2CDQ34097510-479ADFD7-F0CB-4716-A9A5-EC5D9F053561Q34203868-687BD314-D510-4FBC-92F7-9A199B129B45Q34351481-D38D18BE-5332-4A56-AF70-078F0D010E01Q34732880-59C69498-0DCF-4045-BB30-56ED21522795Q35062935-1A4E0E31-F8A3-4CB5-9455-D7174983BB2FQ35144011-0ECA3B3D-329F-4A40-AE88-FDF1E573D538Q35174480-09DA679A-B15E-4F2F-BA09-1271524BE798Q35230322-9DCBF793-A6CD-4ECC-B455-2E648DABDF2FQ36292445-4CE42804-8991-4B87-98A3-2EAE09324F61Q36293101-2E68092B-CACA-4AAF-8510-1AA6D35CF21CQ36303823-CD279FD7-69E4-4441-9B02-E67700A05224Q36328373-D9691850-65D4-4EAA-81A9-AFE5126BBA95Q36430744-C68B2791-D65A-4FD6-9EBC-76E74605A6C0Q36476775-0935D1C1-45A3-41C2-AD09-BED07EF6BF30Q36563646-5C283E86-E3CB-430C-8891-227074B20817Q36595774-42431FB7-D179-4A04-AD77-2FC768CF4003Q36987110-B77C52C7-EE56-4D52-B4C6-E30C96FDCFA3Q37084126-24F2478B-5F00-4062-A932-A7F51323F3D5Q37145218-78772034-AA47-44F0-A641-34D8B5E50ABAQ37196944-9D2DD2D9-C0D5-4E69-AED8-99069831C276Q37230780-BFFEBAD7-4EE9-4B19-A0F7-62378F62B871Q37386939-C0AC2032-A4CF-4624-92FA-53EE11F14179Q37397597-93F804E6-48F4-4EA7-8770-5261721E7B22Q37531098-048C112F-4344-4A73-9A25-6D677B851EB5Q37605856-3169636C-9866-4F9C-BFE2-9C5F69A052DBQ37883014-AD30ADAA-E73F-472C-A19F-F85A3F411863Q38234728-52E74948-2B87-450F-A7BF-845DAF84D2F8Q38473647-C491289C-8540-4E59-9639-157CE3471832Q39483117-053473D4-F5F9-4C91-B25D-428089D8ADE9Q39782175-72725EFE-D71C-4D9F-BF42-692E9572F47AQ39874095-1BD5C93F-6E49-4202-B024-445550C251DAQ40008016-F978DE6C-976F-4DBF-BE84-CD51BE8C46DAQ41491242-BCF8ED82-489E-4A47-AE50-979EEB95F335Q41650121-43906D1F-1BA7-44DE-B5DC-F48067B198EAQ42174870-3E688C6B-839F-49F3-8644-4051EBCA99A3Q42644941-6EBA469C-7BEB-4C5F-B04E-8D0E553EC916Q42792854-0CE141BD-56AD-4015-A51A-108982FD7601Q43595675-EEE574BF-031C-4E76-8415-2B9E89B00579
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Hormones and prostate cancer: what's next?
@ast
Hormones and prostate cancer: what's next?
@en
Hormones and prostate cancer: what's next?
@nl
type
label
Hormones and prostate cancer: what's next?
@ast
Hormones and prostate cancer: what's next?
@en
Hormones and prostate cancer: what's next?
@nl
prefLabel
Hormones and prostate cancer: what's next?
@ast
Hormones and prostate cancer: what's next?
@en
Hormones and prostate cancer: what's next?
@nl
P1476
Hormones and prostate cancer: what's next?
@en
P2093
P356
10.1093/OXFORDJOURNALS.EPIREV.A000795
P577
2001-01-01T00:00:00Z